Evaluation of In-vivo Antimalarial Activity of Methanol Leaf Extract of Glyphaea brevis in Plasmodium berghei-Infected Mice
Purpose: To evaluate the in-vivo antimalarial activity of the methanol extract of the leaves of Glyphaea brevis in Plasmodium berghei infected mice.
Methods: The phytochemical profile of ethylacetate, n-butanol, and residual aqueous fractions of the methanol extract of G. brevis were determined using standard procedures. Mice, weighing between 15 - 30 g, were used for this study. Plasmodium berghei infected blood (0.2 ml) was used to infect each of 55 mice (5 in 11 groups) intraperitoneally. Animals in the infected groups were treated orally with varying doses (200, 300 and 400 mg/kg body weight) of the ethylacetate, n-butanol and residual aqueous fractions daily, using artemisinin (5 mg/kg body weight per day) as standard drug, over a period of four days. The non-infected (normal control, n = 5) received distilled water (0.2 ml) while the infected control group (n = 5) was administered 0.2 ml normal saline. The suppressive antiplasmodial properties of the fractions as well as the serum concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were determined.
Results: Alkaloids, carbohydrates, cardiac glycosides, flavonoids, saponins, tannins, steroids and triterpenes were present in the extract fractions. The suppressive antiplasmodial activity of n-butanol, residual aqueous portion and ethylacetate fractions was 76.64, 73.25 and 72.99 %, respectively, while that of artemisinin was 86.13 %. The serum concentrations of AST, ALT, and ALP in the infected control group were significantly higher (p < 0.05) than those of the treated malaria-infected groups treated with the three fractions.
Conclusion: Glyphaea brevis possesses significant antiplasmodial properties and could be a source of lead molecules for the development of new antimalarial agents.
Keywords: Antimalarial, Glyphaea brevis, Plasmodium berghei, Artemisinin
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.